News headlines about Bruker (NASDAQ:BRKR) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Bruker earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 45.8153027498681 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Bruker (NASDAQ BRKR) traded down $0.77 during trading hours on Tuesday, hitting $34.20. 414,849 shares of the stock traded hands, compared to its average volume of 486,207. The company has a current ratio of 2.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $5,320.00, a P/E ratio of 36.38, a PEG ratio of 2.63 and a beta of 1.12. Bruker has a one year low of $21.83 and a one year high of $36.53.
Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, November 2nd. The medical research company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.27 by $0.02. The company had revenue of $435.60 million during the quarter, compared to the consensus estimate of $415.45 million. Bruker had a net margin of 8.85% and a return on equity of 25.83%. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.32 earnings per share. equities research analysts predict that Bruker will post 1.19 earnings per share for the current year.
Several research firms recently issued reports on BRKR. Zacks Investment Research upgraded shares of Bruker from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a report on Wednesday, November 8th. Bank of America upgraded shares of Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 target price on the stock in a report on Friday, November 3rd. Cowen restated a “hold” rating and issued a $29.00 target price on shares of Bruker in a report on Friday, November 3rd. BTIG Research started coverage on shares of Bruker in a research note on Friday, January 5th. They issued a “buy” rating and a $42.00 price target for the company. Finally, BidaskClub downgraded shares of Bruker from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 11th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $32.38.
Bruker Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.